Effect of esomeprazole triple therapy combined with Bifidobacterium tetrad viable tablets on the eradication rate of Helicobacter pylori positive duodenal ulcer and the levels of IL-6 and TNF-α

Abstract

Objective To investigate the clinical effect of esomeprazole triple therapy combined with Bifidobacterium tetrad viable tablets on duodenal ulcer with Helicobacter pylori (Hp) positive. Methods The clinical effects of esomeprazole triple therapy combined with Bifidobacterium tetrad viable tablets in 47 patients with Hp-positive duodenal ulcer in the Third People’s Hospital of Shuozhou were retrospectively analyzed, it was compared with 46 patients treated with esomeprazole triple therapy (control group). The eradication rate of Hp, clinical efficacy, remission time of symptoms (abdominal pain, abdominal distention) and serum levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were observed and compared between the two groups, the adverse reactions and quality of life scores of the two groups were also statistically analyzed. Results The eradication rate of Hp of observation group was 89.36% (42/47), which was higher than that of control group [69.57% (32/46)], the differences were significant(P 0.05). After 2 weeks of medication, the scores of the quality of life in body health, social function, material life and mental health of observation group were higher than those of control group, the differences were significant(P<0.05). Conclusions The combination of esomeprazole triple therapy and Bifidobacterium tetravaccine tablets in the treatment of Hp positive duodenal ulcer can shorten the relieving time of symptoms, relieve the inflammatory reactions, and improve the eradication rate of Hp. Besides, it’s effective and safe, and it helps to improve the quality of life of the patients. Key words: Duodenal ulcer; Helicobacter pylori; Positive; Esomeprazole triple therapy; Bifidobacterium tetravaccine tablets